Key result
A novel immunoaffinity LC/MS assay revealed that the ratio of active BNP1-32 to total BNP in 11 heart failure subjects was <8%.
A novel IA-LC/MS assay was developed to specifically measure the active form of BNP, revealing that active BNP1-32 constitutes less than 8% of total BNP in heart failure patients.
Answers are grounded in this paper and cite their sources.
May warrant caution interpreting total BNP levels in HF; leaves open whether active BNP-specific assays improve diagnosis or prognosis.
Aim: Patients with elevated levels of B-type natriuretic peptide (BNP) and/or NT-proBNP as measured by clinical tests have an elevated risk of heart failure (HF). Despite utility in large clinical studies, both assays are plagued by large biological variability and specificity issues. To address these concerns and further investigate BNP in the HF setting, we developed an LC/MS assay to characterize the ratio of active to total BNP. Results: We have developed and validated a novel immunoaffinity LC/MS assay to measure BNP-derived fragments, as well as ‘total BNP’ in human plasma. The ratio of active BNP1–32 to total BNP in 11 HF subjects was found to be <8%, and the sum of detectable BNP fragments contributed approximately 20% of total BNP. Conclusion: We developed an assay with the specificity to measure the active form of BNP, which may aid in the accurate diagnosis and better management of HF.
No takes yet. Share an insight, caveat, or question.
Chappell et al. (2016) studied Heart failure (n=11). Immunoaffinity LC/MS assay was evaluated on Ratio of active BNP1-32 to total BNP. A novel immunoaffinity LC/MS assay revealed that the ratio of active BNP1-32 to total BNP in 11 heart failure subjects was <8%.
Synapse has enriched 10 related papers. Consider them for comparative context: